Laker, Eva Agnes OdongpinyNabaggala, Maria SarahKaimal, ArvindNalwanga, DamalieAbdu Musubire, Abdu MusubireKiragga, AgnesLamorde, MohammedParkes- Ratanshi, Rosalind2023-06-282023-06-282019Laker, E. A. O., Nabaggala, M. S., Kaimal, A., Nalwanga, D., Castelnuovo, B., Musubire, A., ... & Ratanshi, R. P. (2019). An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir. BMC Infectious Diseases, 19(1), 1-7.https://doi.org/10.1186/s12879-019-3907-51471-2334https://nru.uncst.go.ug/handle/123456789/9019The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients during the roll out of routine viral load monitoring, who had switched to boosted second- line regimens of either atazanavir or lopinavir.enLopinavirSecond-line antiretroviralAtazanavirFirst-line failureArticle